2026 John R. Desjarlais: Biology and Biochemistry Researcher – H-Index, Publications & Awards

D-Index & Metrics

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Biology and Biochemistry	66	8777	8096	3926	3522	247	13892

Discipline name

D-Index

World Ranking

Current World Ranking

National Ranking

Current National Ranking

Publications

Citations

Biology and Biochemistry

8777

8096

3926

3522

247

13892

Biology and Biochemistry

D-Index

Citations

13892

World Ranking

8777

National Ranking

3926

Overview

John R. Desjarlais is affiliated with Pennsylvania State University in the United States. Their research predominantly spans the fields of Medicine and Immunology and Microbiology, with notable work in Immunology, Radiology, Nuclear Medicine and Imaging, Oncology, Molecular Biology, and Biotechnology.

They have focused extensively on topics such as Monoclonal and Polyclonal Antibodies Research, CAR-T cell therapy research, Immunotherapy and Immune Responses, Immune Cell Function and Interaction, Cancer Immunotherapy and Biomarkers, Glycosylation and Glycoproteins Research, and Advanced Biosensing Techniques and Applications.

Desjarlais has contributed to various scientific journals and conference proceedings. Frequent publication venues include:

Regular and Young Investigator Award Abstracts
Cancer Research
European Journal of Pharmaceutical Sciences
JCI Insight
Journal of Clinical Oncology

Among their recent papers are:

Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022, 2021, JCI Insight
Complex PK-PD of an engineered IL-15/IL-15Rα-Fc fusion protein in cynomolgus monkeys: QSP modeling of lymphocyte dynamics, 2023, European Journal of Pharmaceutical Sciences
Preliminary safety and pharmacodynamic (PD) activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in a phase I dose escalation study of patients with selected advanced solid tumors., 2020, Journal of Clinical Oncology
Abstract 2286: XmAb30819, an XmAb®2+1 ENPP3 x CD3 bispecific antibody for RCC, demonstrates safety and efficacy in in vivo preclinical studies, 2020, Cancer Research
Abstract 1860: Bispecific claudin-6 x CD3 antibodies in a 2 + 1 format demonstrate selectivity and activity on human ovarian cancer cells, 2021, Cancer Research

The scientist has collaborated frequently with colleagues including Rumana Rashid, Christine Bonzon, Kendra N. Avery, Matthew J. Bernett, and Umesh S. Muchhal, reflecting a network of collaborative research engagement.

Best Publications

OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION

Gregory Alan Lazar;Arthur J. Chirino;Wei Dang;John Rudolph Desjarlais

1078
Citations
Enhanced antibody half-life improves in vivo activity

Jonathan Zalevsky;Aaron K Chamberlain;Holly M Horton;Sher Karki

757
Citations
Optimized Fc Variants

Gregory Alan Lazar;Wei Dang;John R. Desjarlais;Sher Bahadur Karki

557
Citations
De novo design of the hydrophobic cores of proteins.

John R. Desjarlais;Tracy M. Handel

485
Citations
Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells

John O. Richards;Sher Karki;Greg A. Lazar;Hsing Chen

456
Citations
Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia

Holly M. Horton;Matthew J. Bernett;Erik Pong;Matthias Peipp

396
Citations
FC variants with altered binding to FCRN

Aaron Keith Chamberlain;John R. Desjarlais;Sher Bahadur Karki;Greogory Alan Lazar

389
Citations
Use of a zinc-finger consensus sequence framework and specificity rules to design specific DNA binding proteins.

John R. Desjarlais;Jeremy M. Berg

350
Citations
Toward rules relating zinc finger protein sequences and DNA binding site preferences.

John R. Desjarlais;Jeremy M. Berg

329
Citations
Inactivation of TNF signaling by rationally designed dominant-negative TNF variants.

Paul M. Steed;Malu G. Tansey;Jonathan Zalevsky;Eugene A. Zhukovsky

319
Citations
Fc VARIANTS WITH OPTIMIZED PROPERTIES

Gregory Alan Lazar;Wei Dang;John R. Desjarlais;Sher Bahadur Karki

318
Citations
Rational design and engineering of therapeutic proteins.

Shannon A. Marshall;Greg A. Lazar;Arthur J. Chirino;John R. Desjarlais

307
Citations
De novo design of the hydrophobic core of ubiquitin.

Greg A. Lazar;John R. Desjarlais;Tracy M. Handel

284
Citations
Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective.

John R. Desjarlais;Greg A. Lazar;Eugene A. Zhukovsky;Seung Y. Chu

244
Citations
Fc Variants With Optimized Fc Receptor Binding Properties

John R. Desjarlais;Sher Bahadur Karki;Gregory Alan Lazar;John Owen Richards

236
Citations
Protein design automation for protein libraries

Joerg Bentzien;Bassil I. Dahiyat;John Desjarlais;Robert J. Hayes

226
Citations
Side-chain and backbone flexibility in protein core design.

John R. Desjarlais;Tracy M. Handel

221
Citations
Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies

Seung Y. Chu;Igor Vostiar;Sher Karki;Gregory L. Moore

215
Citations
A molecular immunology approach to antibody humanization and functional optimization.

Greg A. Lazar;John R. Desjarlais;Jonathan Jacinto;Sher Karki

210
Citations
From coiled coils to small globular proteins: Design of a native-like three-helix bundle

James W. Bryson;John R. Desjarlais;John R. Desjarlais;Tracy M. Handel;William F. Degrado

188
Citations